PriMo Biotechnology Equate 2026 IPO Target to build radiophautical education strategy

PriMo biotechnology assured capital and target 2026 IPO

Taiwan, July 02, 2025 (2025) With all of the capital, lift its path to leaders in Radioligand. The company also revealed the plan to open its IPO in 2026, give R & D extension and international capabilities.

Water the facility that receives the scientific certificate in December, the capital is accelerated by our additional development of drug development. We also plan to file in the TPEX stock panel (ESB).

PMO recently received an official authorization from an ABX advancement compound, the world leader in Taiwan[18F]Psma-1007). “The item has been approved in France, Germany, and the other countries.

In addition to the Glang Cancer Diagnosis, Primo is also progressing medical experimental plan for the Speed ​​PB011 and PB012 to grow other cancer indicators. By leveraging the type of Taiwan’s new registration – such as indication, primo can bring the goods to the next, and a new chemical unit). This strategy helps faster paths in the market, which is expected to accelerate the next investment in radiopharm.

About PMO Biotechnology Company Primo, Ltd.
PMO Biotechnology Company. With international certified sites and cuts, primo are intended to move into a molecular technology and reinforcement for world cancer. Headquarters in Taipei, primo cooperates with international and foreign partners to speed up the progress in GMP development. For more information, please visit https https https https https https https:40otech Primotech on Facebook and Linkedin.